Enanta Pharmaceuticals (ENTA) logo

Enanta Pharmaceuticals (ENTA) stock

Small molecule drugs , market cap $233M

$7.62
-4.51%

Why is ENTA down?

Down 34% from Nov 11 to Nov 20 while the S&P 500 fell 9%.

“The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET/MAVIRET.”

Enanta Pharmaceuticals' Nov 16 release said

Sources: Price history, Nov 20, 2026; Company release, Nov 16, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ENTA moves

Free account, no card. An optional alert when ENTA moves or its score changes.Pro, $1 for a first month. An optional alert when ENTA moves or its score changes.Pro, 7 days free with a card. An optional alert when ENTA moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on ENTA →3 more reasons why ENTA fell 34% since Nov 11, from its filings, with the other side, the company's words, the timeline, and its peers, for Pro members.
Quality Score
-10
Poor
In its industry
#261of 273
Checks firing
0of 14
Trending down
From 52-week high
-55.6%
under its best in a year

Follow ENTA's trial news. Pro members can get an alert when Enanta Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ENTA files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026”Filing with regulators · SEC filing · Aug 10

Key facts on ENTA

Key facts on ENTA
Holding it backSales down 20% $79.2M → $63M in 3 years
Latest filing10-K, Nov 18 Filed its annual report (10-K) for the year to Sep 30, 2026

What's next

Wed Dec 2: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Expected to report Mon Feb 8, after the close

After its last 4 reports it closed -6.1% on average, higher 1 of 4 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

ENTA catalysts

Coming up

5 more coming up, with sizes and sources, for Pro members.

What's next for ENTA, and how long its cash lasts

Next step the company has named

2H 2026“On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026”Filing with regulators · SEC filing · Aug 10

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program
EPS-3903
Another trial
RESOLVEPhase 2/3 · Recruiting · 860 people · main data estimated Jul 2029 · NCT07908381

2 more trials, 2 with data due this year, 5 more milestones and 29 filings, for Pro members.

Cash runway

The company says its cash lasts into Fiscal 2029 (8-K, Nov 16).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Feb 11, 2026)
  • At-the-market share sales program (424B5, filed Jul 2, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

An officer, Kathleen S. Capps, sold 323 shares on Dec 5, 2025.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jay Luly’s 10 filings and quotes.

Get an alert when ENTA files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ENTA ranks in Biotech

ENTA is #261 of 273 by Quality Score.

How ENTA ranks in Biotech
RankStockQuality Score
261Enanta Pharmaceuticals (ENTA) logoENTAEnanta Pharmaceuticals-10

More in Biotech

When does ENTA report earnings, and what happens after?

Expected to report Mon Feb 8, after the close (in 79 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ENTA reported on Nov 16, 2026

The quarter

Sales of $12.9M, 15% less than a year ago; a loss of $0.81 a share, from $0.87.

“The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ENTA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase in the quarter and year-over-year interest expense was due to an increase in forecasted royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® during the first half of Enanta’s 2026 fiscal year.”

From its results filing (SEC filing · Nov 16)

1 more sentence, for Pro members.

The numbers

Market value
$233M
today
Sales
$63M
down 3.6% on the year
Free cash flow
-$42.8M
last 12 months

Sales fell 8.3% a year over 5 years, fiscal 2021 to 2026.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ENTA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-6.0%-2.1%-18.6%
May 11Aug 10Nov 16
ReportedGapReaction5
days
Nov 16, 2026After close-3.9%-18.6%not yet
Aug 10, 2026After close-0.5%-2.1%-7.1%
May 11, 2026After close-5.6%-6.0%-13.0%

ENTA closed higher after 1 of its last 4 reports.

All 4 reports, and ENTA's Quality Score going into each

ENTA sales and profit by year

Sales and profit by year

Sales fell every year from 2019 to 2026, to $63M. It made a profit in one of the eight years.

Nothing is firing on ENTA right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ENTA, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ENTA RSI on Nov 20: 25.3, below its 50-day and 200-day averages

Not scored

RSI 25.3, MACD below signal, below both averages. Not scored.

The deep dive on ENTA

  • What it does and how it makes money3 findings"We have received the full $330.0 million of contractual milestone payments under the agreement related to clinical development and commercialization regulatory approvals of these regimens in major markets, and we continue to earn royalties on sales of the second-generation regimen." (10-K for fiscal 2026)SEC filing · Nov 18, 2026
  • Where it stands3 findingsFor Pro members3 findings on where ENTA stands: its cash, debt, and share count, for Pro members
  • What changed in its filings10 findings"The Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit and, in June 2026, the Federal Circuit affirmed the decision of the District Court and ruled that the claims of the ’953 Patent were invalid." (10-K for fiscal 2026)SEC filing · Nov 18, 2026A new heading in its "Risk Factors" this year: "We have incurred net losses in recent fiscal years and expect to continue to incur operating losses for the foreseeable future, and our results of operations may fluctuate significantly from period to period." (10-K for fiscal 2026; not in fiscal 2025's)SEC filing · Nov 18, 2026, against the one of Nov 19, 2025
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ENTA, for Pro members

15 more findings on ENTA, each with its source, for Pro members.

ENTA share count over time

Shares: 35.9% more than a year ago (to Sep 30).

Shares of ENTA outstanding, as filed
Shares
outstanding
As
of
29.2MNov 6, 2026
29.1MAug 7, 2026
29.1MMay 5, 2026
29MFeb 5, 2026
Offerings, shelves, and splits of ENTA, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $75M of shares, about 32% of its market valueJul 2, 2026
Registered shares for a later sale (S-3)Feb 11, 2026
Raised $65M in a sale of shares, about 28% of its market valueOct 1, 2025
Registered shares for a later sale (S-3)Nov 22, 2023

ENTA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold ENTA?

In ETFs: ENTA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Inc is a biotechnology company that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs with an emphasis on viral infections and immunological diseases. The company has single operating segment.

74 employeesWatertown, MAenanta.com

What Enanta Pharmaceuticals says it competes with

“We are engaged in segments of the pharmaceutical industry that are highly competitive and rapidly changing.”

From its annual report, SEC filing · Nov 18, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ENTA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ENTA's score around: 9 things
  • 7 more filings explained, a plain line each
  • 5 more things pulling ENTA's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ENTA's Quality Score is -10 (Poor), #261 of 273 in Biotech.

What does ENTA's Quality Score say?

ENTA scores -10 today, which Breakaway calls Poor. It is #261 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 34% from Nov 11 to Nov 20 while the S&P 500 fell 9%. Shares: 35.9% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ENTA's Quality Score?

ENTA scores -10 today, which Breakaway calls Poor (below zero). That is #261 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ENTA's -10.

When does ENTA report earnings?

Expected to report Mon Feb 8, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ENTA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Enanta Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.